Chadi is joined by Dr. Robert Brodsky, President of ASH, and Dr. Mikkael Sekeres, Chair of Communications at ASH, to discuss what led to the recent ASH statement on the ABIM MOC and to gather their reactions to the ABIM response and to what next steps might look like. The guests detail the relationship and progress made between ASH and ABIM since the beginning of the partnership in 2001, the process involved for ASH to eventually release a letter related to the MOC, the contents of the letter, the ABIM’s response to the letter, and next steps needed to make progress toward a better system – including talking to hospitals and payers. If you have been following the ABIM-MOC issue, you cannot miss this podcast.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
